Background: Evidence has suggested that aspirin reduces the incidence of several cancers, but these benefits may not occur with pancreatic cancer.
Methods: A 12-year nationwide longitudinal cohort merged with the health checkup data was divided into "exposure ascertainment period" and "outcome ascertainment period" to avoid immortal time bias. The daily defined dose system was used to indicate the drug exposure.
Results: We found no significant association between aspirin use and incident pancreatic cancer based on HR.
Conclusions: Aspirin does not prevent pancreatic cancer.
Impact: A large Asian cohort study with reliable medication information affirms no impact of aspirin on pancreatic cancer development.
©2019 American Association for Cancer Research.